{"created":"2023-05-15T09:06:17.972729+00:00","id":12939,"links":{},"metadata":{"_buckets":{"deposit":"33cf1ac0-b8b1-4018-882f-b7dbdb73a2ad"},"_deposit":{"created_by":14,"id":"12939","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"12939"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00012939","sets":["1875:1978:1986"]},"author_link":["19172","19173"],"item_2_alternative_title_18":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Molecular targeting agents in kidney transplantation"}]},"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-10-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"42","bibliographicPageStart":"35","bibliographicVolumeNumber":"72","bibliographic_titles":[{"bibliographic_title":"市立札幌病院医誌 = Acta medica nosocomi Sapporo = The Journal of Sapporo City General Hospital"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"分子生物学の進歩により腫瘍免疫、自己免疫、さらには同種移植免疫応答における分子レベルのメカニズムが解明され、作用分子に特異的に作用するいわゆる分子標的薬の開発が相次いでいる。同種臓器移植においては、拒絶反応発生を制御する免疫抑制剤においてその恩恵がある。従来はカルシニューリン阻害剤であるシクロスポリンやタクロリムス、代謝拮抗剤であるセルセプト、さらにステロイドの薬剤の組みあわせが、標準的な導入免疫抑制剤であったが、これに抗CD25モノクロナール抗体であるバシリキシマブや、抗CD20モノクロナール抗体であるリツキシマブが併用され、より有効な拒絶反応阻害や、抗ドナー既存抗体を有する症例への適応拡大に寄与している。また最近保険適応となった、mTOR阻害剤であるエベロリムスもその多様な効果が期待されている。本稿では、腎移植における分子標的薬につき、最近の治験およびその使用法の実際を述べる。","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"市立札幌病院"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0288-6073","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"原田, 浩"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"福澤, 信之"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-21"}],"displaytype":"detail","filename":"l425672135.pdf","filesize":[{"value":"1.8 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"l425672135.pdf","url":"https://sapmed.repo.nii.ac.jp/record/12939/files/l425672135.pdf"},"version_id":"9306b767-127e-4f56-9de6-711773d05784"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"腎移植","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫抑制剤","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"分子標的薬","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"腎移植領域における分子標的薬（特集分子標的薬を用いた治療戦略）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"腎移植領域における分子標的薬（特集分子標的薬を用いた治療戦略）","subitem_title_language":"ja"}]},"item_type_id":"2","owner":"14","path":["1986"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-05-15"},"publish_date":"2014-05-15","publish_status":"0","recid":"12939","relation_version_is_last":true,"title":["腎移植領域における分子標的薬（特集分子標的薬を用いた治療戦略）"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T04:30:17.509796+00:00"}